| Cat. No. | Product Name | Field of Application | Chemical Structure |
|---|---|---|---|
| DCC3024 | Lassbio-1366 | Novel Adenosine A2a Receptor Agonist, Attenuating the Progression of Monocrotaline-induced Pulmonary Hypertension |
|
| DCC3025 | Lassbio-1524 | Novel IKK-β inhibitor, reducing the secretion of TNF-α, IL-1β, IL-6, IL-12, IFN-γ and increased secretion of IL-10, protecting gastrointestinal homeostasis |
|
| DCC3026 | Lassbio-1829 Hydrochloride | Novel orally active IKK2 inhibitor |
|
| DCC3027 | Lassbio-1911 | Novel Potent and Selective Histone Deacetylase 6 (HDAC6) Inhibitor |
|
| DCC3028 | Latonduine A | Natural F508del-CFTR corrector, inhibiting both PARP-3 and -16, regulating the activity of the unfolded protein response activator inositol-requiring enzyme (IRE-1) via modulation of the level of its ribosylation by PARP-16 |
|
| DCC3029 | Latonduine B | Natural F508del-CFTR trafficking corrector, targeting poly(ADP-ribose) polymerase (PARP) |
|
| DCC3030 | Latrunculin A | Disruptor of microfilament-mediated processes |
|
| DCC3031 | Laulimalide | Microtubule stabilzer, potently inhibiting cellular proliferation in cancer cell lines |
|
| DCC3032 | Laxaphycin A | Natural antifungal and cytotoxic agent |
|
| DCC3033 | Laxaphycin B | Natural inhibitor of the proliferation of sensitive and resistant human cancer cell lines and this inhibitory activity is strongly increased in the presence of laxaphycin A |
|
| DCC3034 | Lb30870 | Potent, orally active, selective and direct thrombin inhibitor |
|
| DCC3035 | Lb30889 | Prodrug of LB30870 as potent, orally active, selective and direct thrombin inhibitor |
|
| DCC3036 | L-bmaa Hydrochloride | Neurotoxic amino acid |
|
| DCC3037 | Lc0024 | Novel antibiofilm coating, covalently bindng to a titanium implant surface (LC0024-Ti) |
|
| DCC3038 | Lcat Activator A | Novel activator of Lecithin:cholesterol acyltransferase (LCAT) including some familial mutations, by forming a hydrophobic adduct with Cys31 |
|
| DCC3039 | Lcb03-0110 | Novel potent angiogenesis inhibitor, inhibiting VEGFR-2 and JAK/STAT3 signalling in primary cultured human endothelial cells and cancer cells |
|
| DCC3040 | Lcl-peg3-n3 | Novel clickable linker for estrogen receptor degraders |
|
| DCC3041 | Lcrf-0004 | Novel potent and selective RON receptor tyrosine kinase inhibitor |
|
| DCC3042 | Ldc0496 | Novel potent and selective covalent inhibitor of EGFR and Her2 exon20 insertion mutations, exhibiting selectivity over wild type EGFR and within the kinome |
|
| DCC3043 | Ldc7559 | Novel potent inhibitor of the NOX2-dependent oxidative burst in neutrophils by activating the glycolytic enzyme phosphofructokinase-1 liver type (PFKL) and dampening flux through the pentose phosphate pathway |
|
| DCC3044 | Ldc8201 | Novel potent and selective covalent inhibitor of EGFR and Her2 exon20 insertion mutations, exhibiting selectivity over wild type EGFR and within the kinome |
|
| DCC3045 | Ldd-1819 | Novel dual inhibitor of GSK-3β and aurora kinase A, increasing somatic cell plasticity and inhibiting tumorigenicity |
|
| DCC3046 | Ldd970 | Novel Aurora Kinase A Inhibitor |
|
| DCC3047 | Lddn-0003499 | Novel Src family tyrosine kinase inhibitor with anti-inflammatory effects in response to Aß stimulation of microglia |
|
| DCC3048 | Ldha-in-22y | Novel inhibitor of human lactate dehydrogenase A (LDHA) |
|
| DCC3049 | Ldn-0028574 | Novel Inhibitor of SIRT1; Inhibitor of the human MDM2-p53 interaction |
|
| DCC3050 | Ldn-0044878 | Novel PAK3 kinase inhibitor, inhibiting p53-inactivated cancers |
|
| DCC3051 | Ldn-0070977 | Novel inhibitor of PERK stress-dependent eIF2α phosphorylation with no toxicity to the cells |
|
| DCC3052 | Ldn-0130436 | Novel TDP-43::GFP aggregation inhibitor |
|
| DCC3053 | ldn-112006 | Necroptosis inhibitor |
|
